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Background: The echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma
kinase (ALK) gene rearrangements occur in approximately 5% of lung adenocarcimomas (ACA), leading to ALK
overexpression and predicting response to targeted therapy. To the present, few studies have been focused on the
expression of ALK protein in lung squamous cell carcinomas (SqCC). Only several cases of lung SqCC were reported
expression of ALK protein. No clinical study has been published to explicit the relationship between ALK expression
and the response to targeted therapy in SqCC.
Methods: In this study, we analyzed ALK protein expression with a specific rabbit monoclonal Ig antibody (D5F3
clone) in 207 cases of lung SqCC. The positive cases were confirmed with ALK fluorescence in situ hybridization
(FISH) and RT-PCR.
Results: We found that 3 out of 207 (1.4%) cases of lung SqCC were ALK positive detected by IHC staining, which
were confirmed by ALK FISH and RT-PCR.
Conclusions: Our results indicate that ALK protein expression is not a rare molecular event in SqCC. Although the
frequency of EML4-ALK rearrangements is lower in lung SqCC than that in lung adenocarcinomas, their presence
may provide additional treatment options in lung SqCC. The response of SqCC patients with ALK expression to
target therapy of crizotinib should be explored.
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Despite the extensive research and clinical efforts dedi-
cated to the management of lung cancer in the past dec-
ade, lung cancer remains the leading cause of cancer-
related mortality in China and Western countries [1-4].
Patients with lung cancer account for approximately 1.4
million deaths per year worldwide and approximately
160,000 deaths per year in the United States [5]. His-
tologically, lung cancer is dichotomized into small cell
lung carcinoma and non-small cell lung carcinoma
(NSCLC). NSCLCs represent a diverse entity that can be
subclassified further into distinct histologic subtypes
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unless otherwise stated.(SqCC), large cell carcinoma, large cell neuroendocrine
carcinoma, anaplastic carcinoma, and giant cell carcin-
oma. NSCLCs represent approximately 80% of all lung
cancer subtypes and it is the leading worldwide cause
of cancer related death. Lung SqCC is a common type
of NSCLCs, causing approximately 400,000 deaths per
year worldwide. Most lung cancers are often diagnosed
at advanced stages of the disease, and the mainstay of
therapy is systemic chemotherapy, typically with a
platinum-based regimen. Given that conventional chemo-
therapeutic regimens only marginally improve the out-
come of such individuals, their median survival time is
less than one year after diagnosis. A plateau has been
reached in the efficacy of chemotherapy using nonspecific
cytotoxic agents. Recent progress in understanding the
biology of this tumor, characterization of NSCLC by mo-
lecular typing, particularly in adenocarcinomas of theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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target dominant oncogenic mutations and show improved
response rates in patients with NSCLCs [6-11]. In the re-
cent years, several potential oncogenic drivers have been
identified in patients with NSCLC, including epidermal
growth factor receptor (EGFR), B-Raf (BRAF), Kirsten rat
sarcoma 2 viral oncogene homolog (KRAS), mesenchymal
epithelial transition factor (MET), human epidermal
growth factor receptor 2 (HER2), and andanaplastic
lymphoma kinase gene (ALK). Specifically, the discov-
ery of the biologic and therapeutic importance of
acquired genetic alterations in 2 genes that encode
pharmacologically targetable tyrosine kinases involved
in growth factor receptor signaling, epidermal growth
factor receptor (EGFR) and anaplastic lymphoma kin-
ase (ALK), has changed the way these cancers are di-
agnosed and treated. It is well known that mutations
of the epidermal growth factor receptor (EGFR) gene
are present in some patients with lung adenocarcin-
oma, with the implication that patients with this geno-
type were super responders to EGFR-tyrosine kinase
inhibitors (TKIs), including gefitinib and erlotinib. In
patients with a somatic EGFR mutation, frontline
treatment with an EGFR inhibitor, gefitinib, results in
improved response rate and superior progression-free
survival. This benefit is limited to patients with EGFR
mutation, as patients without the mutation have better
overall response rates and progression-free survival
with combination chemotherapy.
The anaplastic lymphoma kinase gene (ALK) is a
member of the insulin receptor family and encodes a re-
ceptor tyrosine kinase that was originally identified in
anaplastic large-cell lymphoma as a component of the
fused protein NPM-ALK [12,13]. Subsequently, numer-
ous other rearrangements that involve ALK have been
identified, including TPM3-ALK, ATIC-ALK, TFG-ALK,
CLTCALK and TPM4-ALK. In addition to anaplastic
large-cell lymphoma, ALK fusion genes have also been
described in half of the inflammatory myofibroblastic
tumors and rare ALK-positive diffuse large B-cell lymph-
omas [14-17]. Recently, by screening a retroviral com-
plementary DNA expression library generated from a
NSCLC patient tumor sample, a rearrangements in the
anaplastic lymphoma kinase gene (ALK) and echino-
derm microtubule-associated protein-like 4 (EML4) have
been identified as a result of a small inversion within the
short arm of chromosome 2 between the N -terminal
half of EML4 and the intracellular kinase domain of
ALK [18]. EML4-ALK rearrangement has been demon-
strated to be a potent oncogenic drive and a promising
therapeutic target in NSCLC. It defines a distinct mo-
lecular subset of NSCLC, in particular adenocarcinoma
that can benefit by the treatment of ALK-inhibitors
[19-22]. EML4-ALK gene fusions occur in 2% to 7% oflung adenocarcinomas [23-26]. ALK rearrangement-
positive patients treated with a novel ALK inhibitor, cri-
zotinib, showed an overall response rate of 57%, with
72% having a PFS of 6 months or greater. The US Food
and Drug Administration (FDA) has approved crizo-
tinib for advanced-stage, ALK positive lung cancer as
is also recommended by recent guidelines from pro-
fessional organizations, including the American Soci-
ety of Clinical Oncology (ASCO), European Society
for Medical Oncology, and National Comprehensive
Cancer Network (NCCN).
Despite the encouraging new target treatments have
afforded benefits to patients with lung adenocarcinoma, but
unfortunately the same is not true for lung SqCC [27,28].
Notably, the vast majority of ALK gene rearrangements were
observed in lung adenocarcinoma specimens. The incidence
of ALK gene rearrangements in lung SqCC has not been
well documented except few cases were reported [29,30]. In
the present study, we carried out an immunohistochemical
staining in 207 cases of consecutive lung SqCC patients
with a VENTANA anti-ALK (D5F3) specific rabbit mono-
clonal antibody. The positive samples were confirmed with
ALK Fluorescence In Situ Hybridization (FISH).
Materials and methods
Clinical samples
Patients diagnosed with squamous cell lung carcinoma
and the tumor specimens subjected to ALK protein ex-
pression analysis in Jinling Hospital, China, between
2010 and 2014 were included in this study (Additional
file 1). A total of 207 consecutive cases of squamous cell
lung carcinoma were retrieved from Department of
Pathology. The clinicopathologic characteristics were ob-
tained from medical records. The tissue samples in-
cluded 135 cases of surgical resection samples and 72
cases of biopsy samples. The male of female ratio of the
squamous lung carcinoma patients was 181/26. The me-
dian age of the patients was 63 years (range, 37–96
years). On the basis of World Health Organization Clas-
sification of Tumors (WHO), the Pathology and Genet-
ics of Tumors of the Lung, Pleura, Thymus and Heart
(2014), and International Association for the Study of
Lung Cancer/American Thoracic Society/European Re-
spiratory International Multidisciplinary Classification of
Lung Adenocarcinoma [31], in 135 cases of surgical resec-
tion samples, 24 patients had stage I diseases, 31 patients
had stage II diseases, 62 patients had stage III diseases, and
18 patients had stage IV diseases. The study protocol was
approved by the Jinling Hospital Clinical Research Ethics
Committee, China.
Immunohistochemistry
Four μm-thick sections were cut from Formalin-fixed
paraffin-embedded (FFPE) archive lung SqCC tissues
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according to the protocol provided by Ventana Medical
Systems, Inc. and Roche Diagnostics International, Inc.
Briefly, staining will require one serial tissue section for
H&E, a second serial tissue section for VENTANA anti-
ALK (D5F3), and a third serial tissue section for the
Rabbit Monoclonal Negative Control Ig antibody. The
assay uses the OptiView DAB IHC Detection Kit and
OptiView Amplification Kit, and is run on the BenchMark
ULTRA platforms. The VENTANA ALK 2 in 1 Control
Slides are used as a system-level control. Staining was
graded semiquantitatively, as follows: 0 for absent or
barely perceptible expression in rare cells, 1 (low) for weak
to moderate multifocal expression, and 2 (high) for strong
staining in most cells. Positive cases stained with the
VENTANA anti-ALK (D5F3) IHC assay typically display a
strong, granular cytoplasmic signal. Known staining ele-
ments should be excluded, including: light cytoplasmic
stippling in alveolar macrophages, cells of neural origin
(nerve and ganglion cells), glandular epithelial staining,
and cells within lymphocytic infiltrate. Some background
staining also may be observed within normal mucosa
in NSCLC (including mucin) and in necrotic tumor
areas, which also should be excluded from the clinical
evaluation.
Fluorescence in Situ Hybridization (FISH)
Lung SqCC samples that positive for ALK IHC were
subjected ALK FISH. Four μm-thick formalin-fixed,
paraffin-embedded tissue sections were used for evalu-
ation of ALK genetic status. All cases had interphase
FISH performed for ALK rearrangement with the com-
mercial ALK dual color, break-apart rearrangement probe
(GP Medical Technologies, Beijing, China). Hybridization
was carried out according to the protocol provided by the
manufacturer. Briefly, formalin-fixed, paraffin-embedded
samples were sectioned at a thickness of 4 μm. The sec-
tions were deparaffinized using xylene, dehydrated by gra-
dient ethanol, and rehydrated with deionized water. The
prepared slides were washed with 2x SSC, treated with
0.1 mol/L HCl, and digested with pepsin (P700; Sigma-
Aldrich, St. Louis, MO). The slides and probe mixture
were denatured separately. The denatured probe mixture
was pipetted onto slides, and hybridization was performed
in a wet box at 37°C overnight. After being washed, the
air-dried slides were restained with 4’, 6-diamindino-2-
phenylindole before being analyzed. One hundred individ-
ual interphase nuclei per specimen were enumerated
based on localization in the corresponding H&E-stained
sections. Samples were classified as positive for ALK re-
arrangement when 15% or more of nuclei showed split
signals (i.e., red and green signals were separated by ≥2
signal diameters) or single red signals (3′ ALK) were ob-
served. H&E and FISH slides for all cases were reviewedby two pathologists to confirm that scoring was carried
out in the tumor cell population.
EML4–ALK RT–PCR
Total RNA was extracted from the formalin-fixed,
paraffin-embedded tissue with the RNeasy FFPE Kit
(Qiagen, Hamburg, Germany). Reverse transcription and
the detection of EML4–ALK were performed with the
EML4–ALK Fusion Gene Detection Kit (AmoyDx, Xiamen,
China). The primer sets used to amplify EML4–ALK vari-
ant 1, 3a/b, 2, 5′, and 5a/b are included in the kit. PCR was
performed with the following parameters: denaturation at
95°C for 5 min; 15 cycles of 95°C for 25 s, 64°C for 20 s,
and 72°C for 20 s; and 31 cycles of 93°C for 25 s, 60°C for
35 s, and 72°C for 20 s.
Results
ALK immunohistochemistry
All lung SqCC samples were diagnosed combining mor-
phologic appearance and IHC staining including thyroid
transcription factor-1 (TTF-1), transformation-related pro-
tein 63 (p63) and/or cytokeratin (CK5/6) (Figure 1). The in-
tensity of staining ranges from weak, intermediate to
strongly positive. Heterogeneous staining was noted from
the same case. Of the 207 cases by immunohistochemistry,
cytoplasmic expression of ALK was strongly (marker 2) ob-
served in 3 cases with the VENTANA anti-ALK (D5F3),
intermediately (marker 1) stained in 2 cases and weakly
(marker 1) stained in 4 cases (Figure 2).
ALK FISH
All cases of SqCC samples with expression of ALK
(marker 1 and 2) were confirmed by ALK FISH. A
break-apart signal pattern, where one fusion signal and a
single red and green signal pattern was observed in most
nuclei. A few nuclei showed a predominant signal
pattern of deletion of the 5’ region (nuclei with a single
red signal in addition to a fused signal). Six case of
lung SqCC with weak or intermediate staining of ALK
showed FISH negative, while other 3 cases of lung SqCC
with strong staining of ALK showed positive for ALK
FISH (Figure 3).
EML4–ALK rearrangement detected with RT–PCR
We investigated the presence of the EML4–ALK fusion
variant in 30 samples of Sq CC using RT–PCR, which
including 3 samples that were positive for IHC. The
rearrangement-positive was confirmed in these three
samples and rearrangement-negative was found in other
samples.
Discussion
Immunohistochemistry for ALK protein expression has
been available for many years for use in the diagnosis of
Figure 1 Lung SqCC samples were diagnosed combining morphologic appearance and IHC staining including thyroid transcription
factor-1 (TTF-1), transformation-related protein 63 (p63) and/or cytokeratin (CK5/6). A: Hematoxlin and eosin staining. B: IHC staining for
p63. C: IHC staining for CK5/6. D: IHC staining for TTF-1. Original magnification, ×400.
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bodies for use in lymphoma are insufficiently sensitive
for detection at the level at which it is expressed in
ALK-rearranged lung cancers. However, several recent
studies have demonstrated that several relatively new
ALK clones can accurately identify ALK-rearranged lung
ACA as compared with FISH [2,8,29,32,33]. Studies
published comparing the 5A4 antibody with ALK FISH
demonstrated a sensitivity and specificity of 95% to 100%.Figure 2 Representative ALK IHC images. A: Negative. B: Weak expressionAlthough strong staining seems to be 100% specific
for the presence of rearrangement by FISH, weak-to-
intermediate staining has been reported in FISH-
negative tumors. In the present study, we detected 9
cases of positive expression of ALK, which including 3
strong staining, 2 intermediate staining and 4 weak stain-
ing. Three cases with strong staining were positive and
other 6 cases were negative for ALK FISH. Although
break-apart FISH is the standard method for diagnosis,. C: Moderate expression. D: Strong staining. Original magnification, ×400.
Figure 3 Dual-color, break-apart fluorescent in situ hybridization was performed to confirm the ALK expression. The centromeric (green)
and telomeric (red) fland the ALK locus. Splitting of the red and green signals indicates ALK rearrangement. A: No EML4-ALK rearrangement. B, C
and D: EML4-ALK rearrangements. A break-apart signal pattern, where one fusion signal and a single red and green signal pattern was observed
in most nuclei (B and C). A few nuclei showed a predominant signal pattern of deletion of the 5’region (D).
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cult to interpret. Immunohistochemistry for ALK protein
overexpression is a promising screening modality, with
newer antibodies showing excellent sensitivity and specifi-
city for ALK-rearranged lung.
The echinoderm microtubule-associated protein-like 4
anaplastic lymphoma kinase (EML4-ALK) fusion gene
has been identified as a potent oncogenic driver in non-
small-cell lung cancer, in particular adenocarcinoma. It
defines a distinct molecular subset of NSCLC that can
benefit by the treatment of ALK-inhibitors. ALK rear-
rangements have been reported to occur at frequencies
that range from 0.4 to 15% in NSCLC. Some series in-
cluded patient populations likely to be enriched for ALK
rearrangements, however, the average frequency in unse-
lected NSCLC populations is around 3-4%. Though dif-
ferent groups investigated frequency of EML4-ALK
fusion gene in NSCLC, among those NSCLC the sample
number of lung SqCC was not large enough. People payTable 1 ALK rearrangement study reports in squamous cell lu
No. Authors (reference No.) Ethnic group Patient number
1 Wu et al. [32] Asian 75
2 Alrifai et al. [29] Caucasian 1
3 Ochi et al. [30] Asian 1
4 Calio et al. [35] Caucasian 40
RT-PCR: reverse transcriptase-polymerase chain reaction; FISH: fluorescence in situ hmore attentions on lung adenocarcinoma than on lung
SqCC. Eventually, some groups excluded SqCC from
their study on EML4-ALK [2,10,19,34]. Can we elimin-
ate squamous cell carcinoma of the lung from testing of
EML4-ALK fusiong gene? Takigawa et al. recently raised
the question [30]. They reported a 45 years old Japanese
woman diagnosed as squamous cell carcinoma of lung
harbored EML4-ALK gene rearrangement. Interestingly,
Benepal et al. reported that an ALK rearrangement de-
tected by FISH in a 69-year-old Caucasian gentleman di-
agnosed as lung squamous cell carcinoma [29]. Table 1
shows the prevalence of ALK positive SqCC all over the
world [29,30,32,35].
Out results indicate that EML4-ALK fusion gene rear-
rangements occurred in 1.4% lung SqCC in Chinese
population, which is not a rare molecular event and may
have an impact on treatment choice or response to ther-
apy. Although the frequency of these mutations is lower
in lung SqCC than that in lung adenocarcinomas, theirng cancer patients
Methods used in detection of ALK ALK detection
RT-PCR IHC FISH Positive Negative
Yes Yes ND 1(1.33%) 74(98.67%)
ND ND Yes 1 0
ND Yes ND 1 0
ND ND Yes 1(2.5%) 39(97.5%)
ybridization; IHC: immunohistochemical stain; ND: not done.
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this group. The response of SqCC patients with ALK ex-
pression to target therapy of crizotinib should be explored.
A more detailed clinicopathologic study, including exam-
ination of clinical outcomes in ALK positive versus care-
fully matched ALK negative patients, is in progress, results
of which will be reported separately.
Additional file
Additional file 1: The clinical pathological parameters of patients.
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